Literature DB >> 23407894

Expression of histone acetylases p300 and PCAF in pediatric astrocytomas.

Pilar Eguía-Aguilar1, Mario Solís-Paredes1, Paulina Reyes-Cid1, Mario Perezpeña-Diazconti1, Fernando Chico-Ponce de León2, Stanislaw Sadowinski-Pine1, Francisco Arenas-Huertero3.   

Abstract

OBJECTS: The protein 300 (p300) and p300/CBP-binding protein-associated factor (PCAF) are enzymes with histone acetyltransferase (HAT) activity, a function that can become deregulated in different tumors and affect biological responses.
METHODS: Due to the lack of information on the deregulation of these HATs in pediatric tumors, this study evaluated the expression of both the mRNA and proteins of p300 and PCAF in 54 samples of pediatric astrocytomas embedded in paraffin.
RESULTS: PCAF was not expressed in normal brain tissue. In grade I tumors, the expression of p300 (1.1 ± 0.1) and PCAF (1.2 ± 0.11) was greater than those observed in grade III tumors: 0.72 ± 0.15 for p300 and 0.55 ± 0.11 for PCAF, and grade IV tumors: 0.74 ± 0.13 for p300 and 0.55 ± 0.13 for PCAF (p < 0.05). Immunohistochemical staining revealed the same tendency towards a decrease in the expression of the protein as the degree of clinical severity increased. Patients with recurrent grades I, III, and IV tumors had the highest levels of PCAF, compared to those who showed no recurrence (p < 0.05).
CONCLUSIONS: This work describes and confirms that these HATs play important roles in regulating genes and in the biological behavior of pediatric astrocytomas.

Entities:  

Keywords:  Chromatin; GBM; HAT; PCAF; Pediatric astrocytoma; Recurrent; p300

Mesh:

Substances:

Year:  2013        PMID: 23407894     DOI: 10.1007/s00381-013-2046-3

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  13 in total

Review 1.  The PCAF acetylase complex as a potential tumor suppressor.

Authors:  R L Schiltz; Y Nakatani
Journal:  Biochim Biophys Acta       Date:  2000-03-27

Review 2.  Histone acetyltransferases.

Authors:  S Y Roth; J M Denu; C D Allis
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

3.  Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors.

Authors:  C Armas-Pineda; F Arenas-Huertero; M Pérezpeñia-Diazconti; F Chico-Ponce de León; G Sosa-Sáinz; P Lezama; F Recillas-Targa
Journal:  J Exp Clin Cancer Res       Date:  2007-06

4.  Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme.

Authors:  Weifen F Zeng; Kapila Navaratne; Richard A Prayson; Robert J Weil
Journal:  J Clin Pathol       Date:  2007-02       Impact factor: 3.411

5.  Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator.

Authors:  Tamaki Suganuma; Masahiro Kawabata; Tomoko Ohshima; Masa-Aki Ikeda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-17       Impact factor: 11.205

6.  Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival.

Authors:  Jun Li; Hong-Yu Guan; Li-Yun Gong; Li-Bing Song; Nu Zhang; Jueheng Wu; Jie Yuan; Yi-Jie Zheng; Zheng-Song Huang; Mengfeng Li
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 7.  The molecular and genetic basis of neurological tumours.

Authors:  Yuan Zhu; Luis F Parada
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 8.  p300/CBP proteins: HATs for transcriptional bridges and scaffolds.

Authors:  H M Chan; N B La Thangue
Journal:  J Cell Sci       Date:  2001-07       Impact factor: 5.285

Review 9.  Chromatin folding and gene expression: new tools to reveal the spatial organization of genes.

Authors:  Karen E Brown
Journal:  Chromosome Res       Date:  2003       Impact factor: 4.620

Review 10.  Linking the epigenetic 'language' of covalent histone modifications to cancer.

Authors:  S B Hake; A Xiao; C D Allis
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.